Sclerosing cholangitis associated with dabrafenib–trametinib therapy: BRAF/MEK inhibitors should be considered

Hasan Eruzun

doi:10.15403/jgld-6698

Sclerosing cholangitis associated with dabrafenib–trametinib therapy: BRAF/MEK inhibitors should be considered

Authors

Hasan Eruzun Samsun Training and Research Hospital, Department of Gastroenterology, Samsun, Türkiye

DOI:

https://doi.org/10.15403/jgld-6698

Keywords:

secondary sclerosing cholangitis, BRAF, adverse drug reaction

Downloads

Published

2026-03-27

How to Cite

Eruzun H. Sclerosing cholangitis associated with dabrafenib–trametinib therapy: BRAF/MEK inhibitors should be considered. JGLD [Internet]. 2026 Mar. 27 [cited 2026 Apr. 14];35(1):136-7. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/6698